Register Login

All Posts

Antithrombin Assay Supports Fitusiran Therapy

Here’s a link to our 1 April 2025 Sanofi announcement about the FDA approval of Fitusiran® therapy. Sanofi provides the Siemens Healthineers’ INNOVANCE Antithrombin® assay, a chromogenic substrate method, as a companion diagnostic tool to support Fitusiran dosing. A Sanofi-supported study compared eight antithrombin activity assay kits on seven coagulometers to indicate the reagent-instrument combinations […]
read more

More on Rebalancing Therapy: Suppressing Protein S

Click here for your copy of  The World Federation of Hemophilia Shared Decision-making Tool, Hemostatic Rebalancing Therapy. We’ve posted several entries about rebalancing therapy… Pfizer’s Hympavzi® (marstacimab) Anti-TFPI Approved Hemophilia Therapeutics Discontinued Fitusiran Approved March 28, 2025 Fitusiran: A “Rebalancing Agent” Concizumab, A “Rebalancing Agent” August 2024 Quick Question Summary: Rebalancing Therapy Alhemo® (concizumab) Rebalancing […]
read more